Please provide your email address to receive an email when new articles are posted on . In a head-to-head comparison of two left atrial appendage closure devices for patients with atrial fibrillation, ...
SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...
Shortly after scoring an FDA approval for its Amplatzer Amulet structural heart device this month, Abbott delivered late-breaking clinical trial data putting it up against its main competitor, Boston ...
(UPDATED) In patients undergoing left atrial appendage (LAA) occlusion, the Amplatzer Amulet device (Abbott) provides better closure as well as noninferior safety and effectiveness compared with the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback